Averica Discovery Services enters into preferred provider agreement with IRIX Pharmaceuticals

Averica will provide services to IRIX on a preferred provider basis.

Averica Discovery Services supplies a wide variety of chromatography and analytical services to pharmaceutical, biotechnology and other life sciences researchers. Averica works with its clients to speed lead optimization and early development timelines.

The company provides highly pure assay material and it has substantial expertise in the isolation and structure elucidation of impurities – a valuable asset for optimizing chemistry for production of clinical trial drug supplies.

Averica developed its Targeted Isolation process for rapid and accurate isolation of unknown impurities in mixtures. Conventional chromatographic approaches can require weeks of effort to accumulate enough material for isolation and elucidation. Averica’s Supercritical Fluid Chromatography process is much more efficient and produces results in a fraction of the time.

Averica Discovery Services president Dr Jeffrey Kiplinger noted the company’s shared commitment to scientific excellence and outstanding customer service provides a strong rationale for extending its relationship with IRIX.

"The reduction in timeline and costs delivered by our Targeted Isolation approach is a great example of how our services are helping innovative companies develop new medicines more efficiently," Kiplinger added.